NCT05804032 2026-02-18
Lenalidomide, Bortezomib and Dexamethasone Induction Therapy With Either Intravenous or Subcutaneous Isatuximab in Patients With Newly Diagnosed Multiple Myeloma
University of Heidelberg Medical Center
Phase 3 Completed
Clinical Trials
10 trialsNCT01183949 2024-08-02
Effect of AT7519M Alone and AT7519M Plus Bortezomib in Patients With Previously Treated Multiple Myeloma
Astex Pharmaceuticals, Inc.
Phase 1/2 Completed
NCT01788020 2024-05-13
Efficacy of First Line DRC +/- Bortezomib for Patients With Waldenström's Macroglobulinemia
University of Ulm
Phase 3 Completed
NCT00773747 2021-04-30
Study of Vorinostat (MK-0683) or Placebo, in Combination With Bortezomib in Participants With Multiple Myeloma (MK-0683-088 AMN)
Merck Sharp & Dohme LLC
Phase 3 Completed
NCT00038571 2018-10-31
Proteasome Inhibitor PS-341 Relapsed or Refractory B Cell Lymphomas Previously Treated With Chemotherapy
M.D. Anderson Cancer Center
Phase 2 Completed
NCT00108069 2015-11-05
Tamoxifen and Bortezomib to Treat Recurrent Brain Tumors
National Institutes of Health Clinical Center (CC)
Phase 2 Completed
NCT00813150 2014-08-15
Study of Bortezomib and Dexamethasone With or Without Cyclophosphamide in Patients With Relapsed or Not Controllable Multiple Myeloma
Janssen-Cilag G.m.b.H
Phase 3 Completed
NCT00091117 2013-12-16
Bortezomib in Treating Patients With Advanced Cancer and Liver Dysfunction
National Cancer Institute (NCI)
Phase 1 Completed
NCT00298779 2008-06-06
Open-Label Study to Assess the Effect of Omeprazole on the Pharmacokinetics of VELCADE in Patients With Either Advanced Solid Tumors or Non-Hodgkin's Lymphoma.
Millennium Pharmaceuticals, Inc.
Phase 1 Completed
NCT00129207 2008-02-11
Ketoconazole Administration: How it is Affected by the Body and Broken Down and How it Acts on the Body When Used With Velcade
Millennium Pharmaceuticals, Inc.
Phase 1 Completed